GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intech Biopharm Ltd (ROCO:6461) » Definitions » Debt-to-Equity

Intech Biopharm (ROCO:6461) Debt-to-Equity : 1.23 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Intech Biopharm Debt-to-Equity?

Intech Biopharm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$464.65 Mil. Intech Biopharm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$970.41 Mil. Intech Biopharm's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$1,167.85 Mil. Intech Biopharm's debt to equity for the quarter that ended in Dec. 2023 was 1.23.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Intech Biopharm's Debt-to-Equity or its related term are showing as below:

ROCO:6461' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.2   Med: 0.61   Max: 1.37
Current: 1.23

During the past 12 years, the highest Debt-to-Equity Ratio of Intech Biopharm was 1.37. The lowest was 0.20. And the median was 0.61.

ROCO:6461's Debt-to-Equity is ranked worse than
90.18% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6461: 1.23

Intech Biopharm Debt-to-Equity Historical Data

The historical data trend for Intech Biopharm's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intech Biopharm Debt-to-Equity Chart

Intech Biopharm Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.89 0.86 1.37 1.23

Intech Biopharm Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 1.56 1.69 1.90 1.23

Competitive Comparison of Intech Biopharm's Debt-to-Equity

For the Biotechnology subindustry, Intech Biopharm's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intech Biopharm's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's Debt-to-Equity falls into.



Intech Biopharm Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Intech Biopharm's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Intech Biopharm's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intech Biopharm  (ROCO:6461) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Intech Biopharm Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Intech Biopharm's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Intech Biopharm (ROCO:6461) Business Description

Traded in Other Exchanges
N/A
Address
Ruiguang Road, Neihu District, 3rd Floor, No. 36, Lane 358, Neihu, Taipei, TWN
Intech Biopharm Ltd is a biotechnology company. The company develops inhalation products including single or combination generic products and some new combinations or new formulation projects are under development. It develops drugs for the treatment of lung diseases such as asthma.

Intech Biopharm (ROCO:6461) Headlines

No Headlines